Citigroup’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$152M Buy
2,165,414
+685,380
+46% +$35.5M 0.05% 326
2026
Q1
$75.2M Sell
1,480,034
-456,479
-24% -$21.3M 0.03% 495
2025
Q4
$57.1M Sell
1,936,513
-145,527
-7% -$3.95M 0.03% 590
2025
Q3
$53.8M Sell
2,082,040
-361,604
-15% -$10.1M 0.02% 600
2025
Q2
$67.4M Sell
2,443,644
-65,288
-3% -$1.72M 0.03% 486
2025
Q1
$71.1M Buy
2,508,932
+817,727
+48% +$29M 0.04% 443
2024
Q4
$70.3M Buy
1,691,205
+1,099,295
+186% +$52.5M 0.04% 388
2024
Q3
$39.6M Buy
591,910
+138,378
+31% +$12.7M 0.02% 632
2024
Q2
$53.9M Buy
453,532
+25,335
+6% +$3.21M 0.03% 464
2024
Q1
$45.6M Sell
428,197
-74,273
-15% -$7.49M 0.03% 527
2023
Q4
$50M Sell
502,470
-176,908
-26% -$14.9M 0.04% 457
2023
Q3
$70.2M Buy
679,378
+86,811
+15% +$9.68M 0.05% 314
2023
Q2
$72M Sell
592,567
-113,607
-16% -$15.2M 0.05% 324
2023
Q1
$108M Sell
706,174
-379,989
-35% -$62.7M 0.08% 208
2022
Q4
$195M Buy
1,086,163
+294,199
+37% +$48.1M 0.16% 118
2022
Q3
$93.7M Sell
791,964
-141,474
-15% -$21.5M 0.07% 231
2022
Q2
$133M Sell
933,438
-125,245
-12% -$17.9M 0.1% 172
2022
Q1
$182M Sell
1,058,683
-42,605
-4% -$7.17M 0.11% 159
2021
Q4
$280M Buy
1,101,288
+550,315
+100% +$161M 0.15% 115
2021
Q3
$212M Buy
550,973
+195,392
+55% +$72.1M 0.13% 139
2021
Q2
$83.6M Sell
355,581
-169,809
-32% -$30.3M 0.05% 352
2021
Q1
$68.8M Buy
525,390
+71,240
+16% +$10.3M 0.04% 373
2020
Q4
$47.4M Buy
454,150
+236,851
+109% +$24M 0.03% 565
2020
Q3
$15.4M Sell
217,299
-127,096
-37% -$8.86M 0.01% 1067
2020
Q2
$22.1M Buy
344,395
+223,218
+184% +$12.2M 0.02% 771
2020
Q1
$3.63M Sell
121,177
-133,134
-52% -$3.06M ﹤0.01% 1939
2019
Q4
$4.97M Sell
254,311
-85,535
-25% -$1.52M ﹤0.01% 2030
2019
Q3
$5.41M Buy
339,846
+339,805
+828,793% +$5.02M ﹤0.01% 1875
2019
Q2
$1K Sell
41
-783
-95% -$16.8K ﹤0.01% 7681
2019
Q1
$17K Buy
+824
New +$15.3K ﹤0.01% 7034

Other funds holding MRNA

Citigroup's MRNA Position: Q2 2026 in Review

Citigroup increased its Moderna (MRNA) stake by 46% in Q2 2026, buying an estimated $35.5M and bringing the position to 2,165,414 shares worth $152M. The position accounts for 0.05% of the portfolio, ranked #326.

Citigroup first reported a position in MRNA in Q1 2019 and has held it in 30 quarters since. The position peaked at $280M in Q4 2021. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Citigroup held 2,165,414 shares of Moderna worth $152M as of Q2 2026.
  • Citigroup bought 685,380 Moderna shares in Q2 2026, an estimated $35.5M.
  • Moderna made up 0.05% of Citigroup's portfolio in Q2 2026, its #326 holding.
  • Citigroup first reported a position in Moderna in Q1 2019 and has held it in 30 quarters since.
  • Citigroup's Moderna position peaked at $280M in Q4 2021.
  • 780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.